Radiation-induced valvular heart disease

Article written and reviewed by Dr Luca Moretti

Radiation-induced valvular heart disease is a late manifestation of radiation-induced heart disease caused by therapeutic exposure of cardiac structures during treatment for lymphomas, breast, lung, esophageal and other thoracic cancers. Injury evolves slowly from endothelial dysfunction and inflammation to fibrosis, thickening and calcification. The aortic and mitral valves are affected most often, but the true phenotype includes the aortic root, aorto-mitral continuity, annuli and, in some patients, multiple valves.

Diagnosis cannot be based on the oncological history alone. Many survivors reach an age at which degenerative aortic stenosis, mitral annular calcification and coronary artery disease are common; others have received anthracyclines or have constrictive pericardial disease and myocardial fibrosis. Attribution to radiotherapy emerges from the combination of radiation field and dose, long latency, characteristic morphology and the presence of other lesions within the irradiated territory.

The risk observed today is not identical to that seen in cohorts treated decades ago. Historical mantle fields, high doses and limited shielding exposed larger portions of the heart, whereas conformal planning, intensity modulation, breath-hold techniques and reduced treatment volumes have lowered the dose in many settings. Greater survival, however, makes complications that require years to emerge more visible: modern techniques therefore reduce risk but do not make the radiotherapy history irrelevant.

This etiology changes not only the timing of diagnosis but also treatment. Apparently isolated aortic stenosis may coexist with ostial coronary artery disease, a calcified ascending aorta, mediastinal adhesions, pulmonary restriction and tissue fragility. The choice between surgery and a transcatheter procedure should therefore be made by a Heart Team with expertise in cardio-oncology and multimodality imaging rather than derived automatically from a conventional risk score.

Cardiac exposure, latency and determinants of risk

The likelihood of injury depends on the dose absorbed by individual valves and surrounding structures, not only on the dose prescribed to the tumor or the mean heart dose. Beam orientation, fractionation, irradiated volume and individual anatomy produce different dose distributions. When available, the original dosimetric plan allows exposure of the aortic and mitral valves, coronary arteries and ventricles to be reconstructed more accurately than a generic label of “thoracic radiotherapy.”

In studies of Hodgkin lymphoma survivors, the risk of clinically significant valvular heart disease increases with the dose to the valves and has been particularly evident above 30 Gy, but this cohort observation does not constitute an absolute individual threshold. A lower dose does not eliminate risk and a higher dose does not inevitably cause disease. The dose-response effect is modified by age, technique, latency and cardiovascular vulnerability.

Latency is typically long and is part of the biology of the disease itself. During the first decade, mild regurgitation and thickening may appear; with progressive accumulation of fibrous matrix and microcalcifications, often interacting with the degenerative processes of aging, calcific stenosis and severe dysfunction become more frequent after 10-20 years and may be diagnosed more than three decades after treatment.

Young age at treatment lengthens the period during which injury can become manifest and often characterizes survivors of Hodgkin lymphoma or childhood cancers. In breast cancer, laterality, anatomy and technique matter; in lung or esophageal cancer, doses to the heart and great vessels may be relevant. The name of the malignancy is informative but does not replace dosimetry.

Anthracyclines and other cardiotoxic therapies add myocardial dysfunction, altering both tolerance of and interpretation of valvular disease. Moderate regurgitation may become symptomatic when ventricular reserve is reduced; conversely, low flow may mask the gradient of a stenosis. The combination does not prove synergy in every individual, but it requires assessment of the entire oncological treatment rather than radiotherapy in isolation.

Common cardiovascular risk factors remain modifiable: hypertension, diabetes, dyslipidemia, smoking, obesity and kidney disease accelerate atherosclerosis and calcification and increase overall risk. There is no evidence that statins or other drugs specifically halt radiation-induced valvular fibrosis, but controlling these factors reduces coronary and vascular events in an already exposed population. Secondary prevention should not wait for severe stenosis to develop.

Modern radiation doses are lower on average, but their distribution may be heterogeneous. Proton therapy or breath-hold techniques reduce exposure in selected settings, whereas tumors close to the heart may require trade-offs. Future risk should be discussed without compromising oncological efficacy: the priority is to jointly optimize tumor control and organ sparing while documenting the information that will be needed for long-term surveillance.

Radiation-induced heart disease is neither contagious nor a cancer recurrence. It is a late tissue consequence that may emerge when the patient is no longer followed by the original oncologist. Recording the site, year, dose and field of radiotherapy in the permanent medical history prevents a murmur from being interpreted as simple degeneration and makes it possible to investigate the coronary arteries, pericardium, myocardium and conduction system at the same time.

Fibrosis, calcification and the aorto-mitral phenotype

Ionizing radiation damages the endothelium and microcirculation, generates reactive species and activates profibrotic cytokines. Capillary loss, tissue ischemia and fibroblast transformation increase collagen and extracellular matrix; over the years, osteogenic differentiation and calcium deposition also occur. The process is not a stable “burn,” but progressive remodeling that may simultaneously affect valves, myocardium, pericardium, arteries and the conduction system.

Left-sided structures are exposed to high mechanical pressures and are more often clinically involved. In the mitral valve, thickening affects the base and middle portion of the leaflets, the annulus and the aorto-mitral continuity, with relative sparing of the leaflet tips and commissures compared with rheumatic heart disease. In the aortic valve, the cusps and root become fibrotic and calcified. A thickened aorto-mitral curtain is a characteristic finding and an indicator of surgical complexity.

The early phase often produces regurgitation through retraction and incomplete coaptation. As fibrosis and calcium accumulate, obstruction becomes predominant, particularly as aortic stenosis, whereas the mitral valve may develop regurgitation, stenosis or a mixed lesion. This sequence is not obligatory in an individual patient, and significant stenosis may appear without previously documented regurgitation.

The tricuspid and pulmonary valves are less often sites of important organic injury, partly because of dose and field distribution, but they should still be assessed. Tricuspid regurgitation is frequently secondary to pulmonary hypertension, left-sided dysfunction or right-heart remodeling; attributing it directly to radiation requires primary morphological abnormalities. Multivalvular disease increases the risk that a procedure on a single valve will leave a relevant hemodynamic burden.

Calcification of the aortic root, ascending aorta and mitral annulus may be more extensive than echocardiography suggests. A porcelain aorta complicates clamping, cannulation and suturing and increases embolic risk; calcification of the aorto-mitral continuity may require complex reconstructive surgery. These findings do not by themselves measure the severity of valvular dysfunction, but they change the feasibility and risk of surgery.

The clinical picture is rarely confined to the valve. The pericardium may become thickened, adherent or constrictive and the myocardium may develop interstitial fibrosis and diastolic dysfunction, so that dyspnea, increased atrial pressures and congestion often result from the sum of several components. Even after effective valve correction, persistent symptoms therefore do not necessarily imply prosthetic dysfunction: constriction, restriction, coronary artery disease and pulmonary injury may limit recovery.

The coronary arteries, especially ostial and proximal segments within the radiation field, may develop accelerated atherosclerosis and fibrosis. Silent coronary artery disease changes the risk and valve strategy, but coronary calcification on CT is not always sufficient to define stenosis. Anatomical or functional assessment is selected according to age, symptoms, probability and the planned procedure, with a low threshold for accurate evaluation before intervention.

The differential diagnosis includes calcific degeneration, bicuspid aortic valve, rheumatic heart disease, endocarditis and drug-induced valvular heart disease. Involvement of the root and curtain, sparing of the mitral leaflet tips and the presence of other lesions within the radiation field support a radiation-induced origin. Multiple causes may coexist: radiation and aging are not mutually exclusive categories.

Cardio-oncology surveillance and multimodality imaging

Diagnostic prevention begins before radiotherapy with a cardiovascular history, physical examination and assessment of risk factors; a baseline echocardiogram is indicated according to the clinical profile and treatment plan. Recording pre-existing valvular heart disease prevents incorrect attribution and may alter treatment planning. During radiotherapy, acute symptoms are assessed, but typical structural valvular disease is a late complication and does not require weekly monitoring.

Over the long term, cardio-oncology guidelines and consensus documents recommend risk-based surveillance. The EACVI/ASE document indicated annual clinical assessment, immediate echocardiography if symptoms or signs develop, and screening at ten years in asymptomatic patients, brought forward to five years in high-risk individuals, then approximately every five years. The 2022 ESC guidelines integrate dose, concomitant therapies and overall risk; no schedule replaces individual clinical judgment.

A five-year interval is intended for patients without significant valvular heart disease. Once a lesion is identified, follow-up frequency is determined by severity, ventricular status, symptoms and rate of progression, as for other etiologies, sometimes with closer attention to the combined burden. A new murmur, dyspnea, syncope, angina, edema or unexplained reduction in functional capacity requires assessment without waiting for the scheduled examination.

Transthoracic echocardiography defines both the severity of the valve lesion and the context in which it occurs. In addition to quantifying stenosis and regurgitation, chamber dimensions and pulmonary pressure, it should describe the pericardium, distribution of thickening and calcium, mobility of the mitral leaflet margins, aorto-mitral continuity and right-sided valves. Low flow caused by myocardial fibrosis may, for example, produce severe low-gradient aortic stenosis, whereas constriction alters filling and pressures: a single Doppler measurement must therefore always be interpreted within the entire radiation-induced phenotype.

Transesophageal echocardiography, including three-dimensional imaging, clarifies valve anatomy and mechanism when acoustic shadowing from calcium or thoracic windows limit transthoracic imaging. It is useful for planning mitral repair or replacement and for excluding endocarditis. Esophageal fibrosis or previous treatments may increase its risk: indication and safety should be verified rather than treating probe insertion as an automatic step.

Cardiac CT is central to planning. It defines calcium in the cusps, annuli, curtain and ascending aorta, relationships with the sternum, vascular access, coronary arteries and TAVI anatomy. Aortic valve calcium scoring helps in discordant stenosis according to validated criteria, but the presence of extensive calcium in an irradiated structure does not by itself constitute an indication for intervention. CT should answer precise clinical questions and the additional radiation dose should be optimized.

Cardiac magnetic resonance imaging measures volumes, function, flows and myocardial fibrosis and may help distinguish constriction from restriction when integrated with other data. It is useful when regurgitation and remodeling are discordant or when associated cardiomyopathy is suspected. Artifacts, devices and claustrophobia may limit it; it does not replace CT for calcification or echocardiography for subtle leaflet dynamics.

Functional assessment with exercise testing may distinguish deconditioning, pulmonary disease and cardiac limitation, but it must be interpreted cautiously when multiple lesions are present. Natriuretic biomarkers indicate stress, not etiology. Integrated imaging combines anatomy, hemodynamics and extracardiac injury so that treatment is not decided on valve area alone or on the history of radiotherapy alone.

Preoperative assessment and overall cardiopulmonary risk

Severe symptomatic valvular heart disease generally meets the indications for the corresponding native-valve lesion, but the method of correction requires broader assessment. Common surgical risk scores may not capture mediastinal fibrosis, a calcified aorta, adhesions, irradiated lung and tissue fragility. The Heart Team should estimate not only procedural mortality but also the probability that the valve is truly the main cause of symptoms.

The oncology record clarifies cancer status and prognosis, future therapies and risk of recurrence. A history of cancer does not automatically exclude intervention; active disease does not always imply a short prognosis. The oncologist and cardio-oncologist help define life expectancy, interactions with antithrombotic therapy, the need for other procedures and the patient’s goals.

CT assesses a porcelain aorta, the distance of structures from the sternum and annular calcification. Coronary imaging determines whether revascularization is needed and whether future transcatheter access will remain feasible. An irradiated or stenotic internal mammary artery may not be a reliable conduit; previous procedures and radiation fields may make re-entry into the chest riskier. Planning without these data exposes the patient to avoidable intraoperative surprises.

Before attributing symptoms to the valve alone, the contribution of the pericardium and myocardium must also be defined. Significant constriction may require pericardiectomy, whereas advanced restrictive cardiomyopathy may limit the benefit of isolated valve replacement; when pressures and mechanisms remain uncertain, right- and left-heart catheterization helps separate them. The therapeutic decision must therefore distinguish correctable disease from irreversible or concurrent injury.

Pulmonary function testing and chest imaging quantify fibrosis, effusions and respiratory reserve. Dysphagia, esophageal stenosis, thyroid abnormalities, sternal fragility and skin healing may influence anesthesia and access. These factors explain why multidisciplinary assessment is a substantive part of treatment rather than a formal step after the procedure has already been chosen.

In multivalvular disease, it is necessary to estimate which lesions contribute to symptoms and which may progress. A second operation in an irradiated mediastinum is particularly demanding, but adding extensive procedures increases the risk of the first intervention. There is no rule requiring correction of every moderate lesion: the strategy balances disease burden, expected durability, future transcatheter access and the feasibility of a complete solution.

Calcification of the aorto-mitral curtain may require complex fibrous reconstruction and increases the risk of bleeding, dehiscence and conduction injury. The technical threshold depends on center experience. Patients requiring surgery should be referred to a Heart Valve Centre capable of combining aortic, mitral, coronary and pericardial surgery with cardio-oncology support.

Frailty, nutrition and patient preferences complete the selection process. A less invasive intervention may offer faster recovery but is not automatically more durable or complete; complex surgery can address multiple components but is not justified if cardiopulmonary reserve precludes benefit. Shared decision-making makes uncertainty and the possibility of residual symptoms explicit, avoiding both oncological nihilism and procedural technicism.

Surgery, transcatheter procedures and long-term prevention

Surgery has the advantage of addressing multiple valves, coronary arteries, the aorta and pericardium in the same procedure and remains appropriate when anatomy, age and concomitant disease make complete correction preferable. It should nevertheless be recognized that observational studies report worse long-term outcomes after cardiac surgery in previously irradiated patients than in controls, at least partly because of diffuse cardiopulmonary injury. These data help define risk and plan the intervention; they do not in themselves constitute a contraindication.

In aortic stenosis, TAVI avoids sternotomy, clamping of a calcified aorta and mediastinal dissection. Cohort studies and meta-analyses suggest favorable early outcomes in many patients with previous radiotherapy, but selection, age and anatomy prevent generalization. Access routes, coronary arteries, annulus, risk of occlusion, pacemaker implantation, leak and prosthesis durability should be assessed as in any TAVI, while also considering the perspective of radiation-induced heart disease.

TAVI does not treat severe mitral disease, constriction or coronary arteries that cannot be addressed. In younger patients with long life expectancy, durability and the possibility of TAVI-in-TAVI or future coronary access become central considerations. The correct recommendation is not “radiotherapy equals TAVI,” but a personalized comparison between actual surgical risk, the ability of an isolated procedure to resolve the clinical picture and a strategy spanning the patient’s entire lifetime.

Radiation-induced mitral disease is particularly complex. Regurgitation with rigid leaflets and calcification may be poorly suited to surgical repair or edge-to-edge repair; stenosis and annular calcification make replacement risky and transcatheter implantation highly selective. CT and transesophageal echocardiography define the risk of left ventricular outflow tract obstruction, embolization and leak. Transcatheter options are reserved for experienced centers and do not have evidence comparable with TAVI for aortic stenosis.

When a prosthesis is implanted, the choice between mechanical and biological valves takes into account age, bleeding, anticoagulation, malignancy, future procedures and reintervention risk. Radiation alone does not determine prosthesis material. In some patients, avoiding future re-entry favors a more durable strategy; in others, chronic anticoagulation or oncological needs make a bioprosthesis with possible valve-in-valve treatment preferable.

Follow-up does not end with successful valve correction because other valves, coronary arteries, the pericardium and myocardium may continue to evolve and the prosthesis requires its own surveillance. New dyspnea should therefore be reassessed without automatically attributing it either to cancer recurrence or to prosthetic dysfunction. Rehabilitation, adapted physical activity, nutrition and risk-factor control support functional reserve even though they do not directly modify established fibrosis.

Primary prevention of cardiotoxicity belongs to oncological planning: minimize dose to the valves and heart while maintaining cancer control, use sparing techniques, consider anatomy and document dosimetry. There is no universal “safe” dose and the oncological benefit remains the priority. Good planning does not eliminate the need for surveillance, but it reduces the expected burden in future generations of survivors.

Clinical prevention consists of maintaining a record of exposure for decades. Giving the patient a summary of the malignancy, radiation field, dose, chemotherapy and follow-up schedule provides continuity among oncology, primary care and cardiology. Radiation-induced valvular heart disease is often silent until an advanced stage; recognizing it through a program proportionate to risk provides the time needed to select an intervention before myocardial, pulmonary or end-organ injury makes benefit unlikely.